Activating RAS mutations have the potential for inducing T-ALL in murine models when combined with other genetic anomalies, including enhancer of Zeste 2 (EZH2) inactivation [64] as well as NOTCH1 [65,66] or IL7 receptor (IL7R) α chain mutations [67]. Here, IL7R is linked to acute lymphoblastic leukemia.